Martin William Axon, CFFOH, CMIOSH, SafeBridge Europe, Ltd. - Qepler Summits And Conferences

Martin William Axon, CFFOH, CMIOSH

Senior Scientific Advisor
SafeBridge Europe, Ltd.
Stevenage, United Kingdom
SafeBridge, developer of the Potent Compound Safety Triangle™, provides industrial hygiene, toxicology, and safety services to the pharmaceutical, biotechnology, and fine chemicals industries.

Martin Axon is Principal Occupational Hygienist for SafeBridge Europe and is a Chartered Fellow of the Faculty of Occupational Hygiene; he has degrees in Industrial Chemistry and Environmental Pollution Science. He has over 25 years of experience working in the pharmaceutical industry in the UK and internationally, where, as an occupational hygienist for primary and secondary sites, he provided support for potent pharmaceutical product manufacture. During mid-career he was Course Director for a postgraduate programme in Occupational Hygiene, Health and Safety, at London South Bank University.

Martin joined SafeBridge in 2005. His current role includes managing SafeBridge’s services in Europe and advising clients on the safe handling of potent pharmaceutical compounds in a range of environments, from laboratory scale through to secondary manufacture.

Related Sessions:

2nd Annual Highly Potent APIs
Summit 2020

Assess and reduce manufacturing and handling challenges for highly potent active pharmaceutical ingredients.
  • 19 Feb 2020
  • Prague, CZ
  • Pharma
Day 1: Wednesday, 19 February 2020
CASE STUDY: Assessing Containment Performance of Continuous Table Coating Equipment.
  • Operation of the GEA tablet coater.
  • Working with GEA to make preparations for the project.
  • Assessments during operation and during disassembly/cleaning.
  • Outcomes: suitability of the equipment to process tablets containing potent API.
View Details

2nd Annual Highly Potent APIs
Summit 2020

Assess and reduce manufacturing and handling challenges for highly potent active pharmaceutical ingredients.
  • 19 Feb 2020
  • Prague, CZ
  • Pharma
Day 2: Thursday, 20 February 2020
CASE STUDY: Evaluating a CMO’s Overall Ability to Safely Handle Potent APIs.
  • Management and resource.
  • Evaluating the hazard.
  • Controlling exposure risks.
  • Verifying controls.
  • Design of the facility from an exposure control perspective.
  • Employee understanding of API safety.
View Details

3rd Annual Highly Potent
APIs Summit 2023

Assess and reduce manufacturing and handling challenges for highly potent active pharmaceutical ingredients.
  • 22 Feb 2023
  • Virtual,
  • Pharma
Day 1: Wednesday, 22 February 2023
CASE STUDY: Ultra-Potent Pharmaceuticals: Verifying Containment

The pharmaceutical sector uniquely carries out extensive testing of their products on human subjects. This testing provides data that allows toxicologists to develop safe limits for occupational exposure. However, ultra-high potent pharmaceuticals, with exposure limits below 10 ng/m3 provide challenges by pushing the containment technology and the verification of this technology to the limits of what is achievable.

View Details